ClinicalTrials.gg
CompletedNCT02725515Updated Aug 20, 2019Results posted

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

A Phase 2 interventional study of XmAb5871 and Placebo to match XmAb5871 in Systemic Lupus Erythematosus, sponsored by Xencor, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by Xencor, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
163rd of 407
105 · median 70
Started
2016
with 10 others
Phase 2
120 of 477
10 open now
Registered
217th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 163rd largest by enrollment of the 407 interventional ones that give a count, is one of 11 that started in 2016, is one of 120 in phase 2, and was the 217th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of SLE as defined by the ACR criteria
  • Patients have a history of a (+) ANA, (+) ENA or a (+) anti-dsDNA serology documented within one year prior to randomization
  • Investigator has assessed the patient and in their judgment, the SLE disease activity is not organ threatening
  • Both investigator and patient agree that it is acceptable to discontinue their current SLE medications and receive a brief course of IM therapy
  • If patients are on oral steroids, they must be on the equivalent of ≤15 mg/day of prednisone to enter screening, and must be able to taper to ≤10 mg/day by randomization

Exclusion criteria

Exclusion Criteria:

  • History or evidence of a clinically unstable/uncontrolled disorder, condition or disease, other than SLE that, in the opinion of the investigator would pose a risk to patient safety or interfere with the study evaluation, procedures or completion
  • Patients who have organ threatening manifestations of SLE including active Class 3 or 4 lupus nephritis requiring induction or maintenance therapy or any other disorder for which stopping SLE therapy is
  • Active CNS lupus such as seizures or psychosis that in the opinion of the investigator would preclude participation
  • Unstable hemolytic anemia or thrombocytopenia
  • Patient is pregnant or breast feeding, or planning to become pregnant while participating in the study
  • Use of any biologic therapy (including belimumab) within 6 months of randomization, or prior exposure to a monoclonal antibody directed to CD20 (such as rituximab) within 12 months of randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    XmAb5871

    XmAb5871 administered by IV infusion for up to a total of 16 infusions

    Biological: XmAb5871

  • Placebo comparator
    Placebo

    Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions

    Biological: Placebo to match XmAb5871

Interventions

  • BiologicalXmAb5871
  • BiologicalPlacebo to match XmAb5871
06

What researchers measure

Primary outcomes

  1. Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225

    Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 225

    Time frame: Day 225

Secondary outcomes

  1. Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169

    Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 169

    Time frame: Day 169

  2. Time to Loss of Systemic Lupus Erythematosus Disease Activity Improvement Achieved by a Short Period of IM Steroid Therapy in SLE Patients

    Loss of improvement was defined as worsening of disease activity that in the opinion of the principal investigator requires a change in treatment (exclusive of a decrease in oral steroids) AND one of: 1. SELENA- SLEDAI increase of \>=4 points from maximal improvement OR 2. Worsening of at least 1 BILAG A or B score OR 3. New BILAG A or B score.

    Time frame: From the date of randomization until the date of loss of Systemic Lupus Erythematosus Disease Activity Improvement, or the date of the final efficacy assessment, up to 239 days.

07

Results

Posted Aug 9, 2019
Limitations and caveats
Prior to database lock, an evaluation of early discontinuation rates indicated that the efficacy-evaluable population might be insufficient to power the primary analysis. An additional 15 patients were enrolled beyond the originally planned 90.

Participant flow

First informed consent date: 16FEB2016 First randomization date: 07MAR2016 Last informed consent date: 09NOV2017 Last randomization date: 07DEC2017

Participant flow — Overall Study
MilestoneXmAb5871Placebo
Started5352
Completed2817
Not completed2535
Withdrew: Refused infusion (no study treatment)10
Withdrew: Loss of improvement per protocol1425
Withdrew: Withdrawal by subject21
Withdrew: Non-compliance with study drug03
Withdrew: Lost to follow-up11
Withdrew: Adverse event72
Withdrew: No documented disease improvement01
Withdrew: Completed study under original protocol01
Withdrew: Lack of response01

Outcome measures

PrimaryPercentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225

Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 225

Time frame:
Day 225
Reported as:
Count of participants · Participants
Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225
ParticipantsXmAb5871Placebo
Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 2252112
Statistical analysis
  • XmAb5871 vs Placebo · Barnard's Unconditional Exact Test P-val · p = 0.1830 · Risk difference (rd): 13.4 · 95% CI -6.6 to 32.6
SecondaryPercentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169

Landmark proportion of patients without loss of systemic lupus erythematosus disease activity improvement on Day 169

Time frame:
Day 169
Reported as:
Count of participants · Participants
Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 169
ParticipantsXmAb5871Placebo
Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 1692917
Statistical analysis
  • XmAb5871 vs Placebo · Barnard's Unconditional Exact Test P-val · p = 0.1075 · Risk difference (rd): 17.5 · 95% CI -3.7 to 37.3
SecondaryTime to Loss of Systemic Lupus Erythematosus Disease Activity Improvement Achieved by a Short Period of IM Steroid Therapy in SLE Patients

Loss of improvement was defined as worsening of disease activity that in the opinion of the principal investigator requires a change in treatment (exclusive of a decrease in oral steroids) AND one of: 1. SELENA- SLEDAI increase of \>=4 points from maximal improvement OR 2. Worsening of at least 1 BILAG A or B score OR 3. New BILAG A or B score.

Time frame:
From the date of randomization until the date of loss of Systemic Lupus Erythematosus Disease Activity Improvement, or the date of the final efficacy assessment, up to 239 days.
Reported as:
Median · days
Time to Loss of Systemic Lupus Erythematosus Disease Activity Improvement Achieved by a Short Period of IM Steroid Therapy in SLE Patients
daysXmAb5871Placebo
Time to Loss of Systemic Lupus Erythematosus Disease Activity Improvement Achieved by a Short Period of IM Steroid Therapy in SLE Patients230 (197.0 to 239.0)131 (85.0 to 225.0)
Statistical analysis
  • XmAb5871 vs Placebo · Log Rank · p = 0.0252 · Hazard ratio (hr): 0.53 · 95% CI 0.30 to 0.92

Adverse events

Collected over Adverse event summaries include events reported between randomization and the end of study visit (Day 253). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XmAb58710/52 (0%)7/52 (13.5%)41/52 (78.8%)
Placebo0/52 (0%)4/52 (7.7%)28/52 (53.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventXmAb5871Placebo
Iron deficiency anaemiaBlood and lymphatic system disorders1/520/52
AnaemiaBlood and lymphatic system disorders0/521/52
Atrial fibrillationCardiac disorders1/520/52
EnteritisGastrointestinal disorders0/521/52
PyrexiaGeneral disorders1/520/52
PneumoniaInfections and infestations1/520/52
Infusion related reactionInjury, poisoning and procedural complications1/520/52
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/521/52
MigraineNervous system disorders0/521/52
DizzinessNervous system disorders1/520/52
Most frequent other events
Showing 10 of 29
Most frequent other events
EventXmAb5871Placebo
NauseaGastrointestinal disorders20/529/52
HeadacheNervous system disorders12/521/52
VomitingGastrointestinal disorders9/521/52
Back painMusculoskeletal and connective tissue disorders8/522/52
DizzinessNervous system disorders8/521/52
FlushingVascular disorders7/520/52
Muscle spasmsMusculoskeletal and connective tissue disorders5/526/52
Upper respiratory tract infectionInfections and infestations4/526/52
Pain in extremityMusculoskeletal and connective tissue disorders6/521/52
Urinary tract infectionInfections and infestations5/523/52

Baseline characteristics

Intent to Treat (ITT) Population: All patients who have received at least a partial dose of XmAb5871 or placebo. One patient was randomized to XmAb5871 but was never treated and withdrew from the study. This one patient is excluded from this analysis.

Age, Continuous
Age, Continuous(years)XmAb5871PlaceboTotal
Median45.5 (23 to 65)43.5 (20 to 64)45.0 (20 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)XmAb5871PlaceboTotal
Female504999
Male235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)XmAb5871PlaceboTotal
Hispanic or Latino6410
Not Hispanic or Latino464894
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)XmAb5871PlaceboTotal
American Indian or Alaska Native213
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American262551
White192544
More than one race000
Unknown or Not Reported303
Region of Enrollment
Region of Enrollment(participants)XmAb5871PlaceboTotal
United States5252104
SLEDAI Total Score at Screening--Efficacy Evaluable Population
SLEDAI Total Score at Screening--Efficacy Evaluable Population(units on a scale)XmAb5871PlaceboTotal
Median8.0 (4 to 16)10.0 (2 to 18)10.0 (2 to 18)
08

Study locations

23 sites
  • UC San Diego
    La Jolla, California 92037, United States
  • Loma Linda University
    Loma Linda, California 92354, United States
  • East Bay Rheumatology Medical Group
    San Leandro, California 94578, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06250, United States
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Center For Rheumatology
    Fort Lauderdale, Florida 33309, United States
  • Piedmont Atlanta Rheumatology
    Atlanta, Georgia 30309, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Joshua P June, DO
    Lansing, Michigan 48910, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    Bronx, New York 10461, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • CTRC University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27517, United States
  • DJL Clinical Research
    Charlotte, North Carolina 28210, United States
  • Paramount Medical Research and Consulting LLC
    Cleveland, Ohio 44130, United States
  • Arthritis & Rheumatology Center of Oklahoma, PLLC
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Center for Arthritis Therapy & Research
    Tulsa, Oklahoma 74104, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
09

References and documents

Publications

  • Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630-40. doi: 10.1002/art.1780350606. PubMed 1599520 ↗
  • Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91. PubMed 11838846 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Jul 2018, 29 months.

Results were first posted in Aug 2019, 1 year after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 29 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Apr 1, 2016
StartActual
Feb 16, 2016
Primary completionActual
Jul 17, 2018
CompletionActual
Jul 17, 2018
Results first posted
Aug 9, 2019
Last update
Aug 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02725515
Lead sponsor
Xencor, Inc.
Collaborators
PPD DEVELOPMENT, LP, ICON plc
Responsible party
Sponsor
First posted
Apr 1, 2016
Start date
Feb 16, 2016
Primary completion
Jul 17, 2018
Completion
Jul 17, 2018
Results posted
Aug 9, 2019
Last update
Aug 20, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obexelimab

Start the discussion